STUELPNAGEL JOHN R
SEC Form 4 insider trading activity
STUELPNAGEL JOHN R has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.
On the most recent filing, STUELPNAGEL JOHN R is listed as Director at 10x Genomics, Inc. Inside the rolling window, STUELPNAGEL JOHN R reported no open-market purchases and 2 open-market sales totaling $2.4M in TXG. The largest disclosed transaction in the window is a sale of 20,000 TXG shares on Sep 3, 2026, worth $1.2M.
Companies traded
Other insiders at TXG
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.4M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has STUELPNAGEL JOHN R made?
STUELPNAGEL JOHN R has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does STUELPNAGEL JOHN R trade?
STUELPNAGEL JOHN R has filed SEC Form 4 disclosures for 1 company, including TXG.
When was STUELPNAGEL JOHN R's most recent SEC Form 4 filing?
STUELPNAGEL JOHN R's most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.
What is STUELPNAGEL JOHN R's total buy and sell value in the current window?
Inside the rolling retention window, STUELPNAGEL JOHN R bought $0 and sold $2.4M based on SEC Form 4 filings.
What was STUELPNAGEL JOHN R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 20,000 TXG shares on 2026-09-03, worth $1.2M, per SEC Form 4 filings.